Ablative techniques for hepatocellular carcinoma

2001 ◽  
Vol 28 (5) ◽  
pp. 487-496 ◽  
Author(s):  
Carlton C. Barnett ◽  
Steven A. Curley
Keyword(s):  
Hepatocellular Carcinoma ◽  
Ablative Techniques

Technology Insight: image-guided therapies for hepatocellular carcinoma—intra-arterial and ablative techniques

2006 ◽  
Vol 3 (6) ◽  
pp. 315-324 ◽  
Author(s):  
Kelvin Hong ◽  
Christos S Georgiades ◽  
Jean-Francois H Geschwind
Keyword(s):  
Hepatocellular Carcinoma ◽  
Image Guided ◽  
Ablative Techniques

scholarly journals Laser Ablation for Small Hepatocellular Carcinoma

2011 ◽  
Vol 2011 ◽  
pp. 1-8 ◽  
Author(s):  
Claudio Maurizio Pacella ◽  
Giampiero Francica ◽  
Giovanni Giuseppe Di Costanzo
Keyword(s):  
Hepatocellular Carcinoma ◽  
Laser Ablation ◽  
Percutaneous Ablation ◽  
Small Hepatocellular Carcinoma ◽  
Term Survival ◽  
Local Experience ◽  
Tumor Lesion ◽  
Therapeutic Choice ◽  
Risk Patients ◽  
Ablative Techniques

Hepatocellular carcinoma (HCC) is one of the most common malignancies worldwide and is increasingly detected at small size (<5 cm) owing to surveillance programmes in high-risk patients. For these cases, curative therapies such as resection, liver transplantation, or percutaneous ablation have been proposed. When surgical options are precluded, image-guided tumor ablation is recommended as the most appropriate therapeutic choice in terms of tumor local control, safety, and improvement in survival. Laser ablation (LA) represents one of currently available loco-ablative techniques: light is delivered via flexible quartz fibers of diameter from 300 to 600 μm inserted into tumor lesion through either fine needles (21g Chiba needles) or large-bore catheters. The thermal destruction of tissue is achieved through conversion of absorbed light (usually infrared) into heat. A range of different imaging modalities have been used to guide percutaneous laser ablation, but ultrasound and magnetic resonance imaging are most widely employed, according to local experience and resource availability. Available clinical data suggest that LA is highly effective in terms of tumoricidal capability with an excellent safety profile; the best results in terms of long-term survival are obtained in early HCC so that LA can be proposed not only in unresectable cases but, not differently from radiofrequency ablation, also as the first-line treatment.

scholarly journals Immunmodulatory Treatment Strategies of Hepatocellular Carcinoma: From Checkpoint Inhibitors Now to an Integrated Approach in the Future

Cancers ◽  
2021 ◽  
Vol 13 (7) ◽  
pp. 1558
Author(s):  
Matthias Ocker ◽  
Christian Mayr ◽  
Tobias Kiesslich ◽  
Sebastian Stintzing ◽  
Daniel Neureiter
Keyword(s):  
Hepatocellular Carcinoma ◽  
Clinical Trials ◽  
Immune Checkpoint ◽  
Checkpoint Inhibitors ◽  
Treatment Strategies ◽  
Human Tumor ◽  
Standard Of Care ◽  
Immune Checkpoints ◽  
Published Data ◽  
Ablative Techniques

Background: Hepatocellular carcinoma (HCC) still represents a human tumor entity with very limited therapeutic options, especially for advanced stages. Here, immune checkpoint modulating drugs alone or in combination with local ablative techniques could open a new and attractive therapeutic “door” to improve outcome and response rate for patients with HCC. Methods: Published data on HCC experimental to pre-(clinical) treatment strategies from standard of care to novel immunomodulatory concepts were summarized and discussed in detail. Results: Overall, our knowledge of the role of immune checkpoints in HCC is dramatically increased in the last years. Experimental and pre-clinical findings could be translated to phase 1 and 2 clinical trials and became standard of care. Local ablative techniques of HCC could improve the effectivity of immune checkpoint inhibitors in situ. Conclusions: This review demonstrates the importance of immunomodulatory treatment strategies of HCC, whereby the “best treatment code” of immune checkpoint drugs, combination with ablative techniques and of timing must be evaluated in coming clinical trials.

scholarly journals Indian Society of Vascular and Interventional Radiology Expert Consensus Statements for Ablation in Hepatocellular Carcinoma: Part II

2020 ◽  
Vol 4 (03) ◽  
pp. 175-183
Author(s):  
Pankaj Gupta ◽  
Shyamkumar N. Keshava ◽  
Naveen Kalra ◽  
Sreedhara B. Chaluvashetty ◽  
Amar Mukund ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Interventional Radiology ◽  
Indian Society ◽  
Percutaneous Ablation ◽  
Consensus Document ◽  
Consensus Statements ◽  
Early Hcc ◽  
Widespread Availability ◽  
Small Hcc ◽  
Ablative Techniques

AbstractLocoregional therapies play an important role in the management of hepatocellular carcinoma (HCC). Percutaneous ablation is one of the most commonly employed nonsurgical methods for treating very early and early HCC. For small HCC, ablation is potentially curative and competes with surgical resection. The widespread availability and the spectrum of ablative techniques mandate uniform approach among interventional radiologists. Thus, it is desirable to have a consensus regarding various aspects of the liver ablation. This article represents a consensus document of the experts from the Indian Society of Vascular and Interventional Radiology involved in the care of patients with HCC. The statements are presented in two parts.

scholarly journals Ablative techniques in hepatocellular carcinoma treatment

2018 ◽  
Vol 4 (6) ◽  
pp. 18 ◽  
Author(s):  
Ehsun Naeem ◽  
Shahab Abid
Keyword(s):  
Hepatocellular Carcinoma ◽  
Ablative Techniques

scholarly journals Current State of Liver-Directed Therapies and Combinatory Approaches with Systemic Therapy in Hepatocellular Carcinoma (HCC)

Cancers ◽  
2019 ◽  
Vol 11 (8) ◽  
pp. 1085 ◽  
Author(s):  
Pedro Viveiros ◽  
Ahsun Riaz ◽  
Robert J. Lewandowski ◽  
Devalingam Mahalingam
Keyword(s):  
Hepatocellular Carcinoma ◽  
Systemic Therapy ◽  
Immune Cell ◽  
Kinase Inhibitor ◽  
Locally Advanced ◽  
Tumor Biology ◽  
Arterial Embolization ◽  
Intermediate Stage ◽  
Current Evidence ◽  
Ablative Techniques

The increasing set of liver-directed therapies (LDT) have become an integral part of hepatocellular carcinoma (HCC) treatment. These range from percutaneous ablative techniques to arterial embolization, and varied radiotherapy strategies. They are now used for local disease control, symptom palliation, and bold curative strategies. The big challenge in the face of these innovative and sometimes overlapping technologies is to identify the best opportunity of use. In real practice, many patients may take benefit from LDT used as a bridge to curative treatment such as resection and liver transplantation. Varying trans-arterial embolization strategies are used, and comparison between established and developing technologies is scarce. Also, radioembolization utilizing yttrium-90 (Y-90) for locally advanced or intermediate-stage HCC needs further evidence of clinical efficacy. There is increasing interest on LDT-led changes in tumor biology that could have implications in systemic therapy efficacy. Foremost, additional to its apoptotic and necrotic properties, LDT could warrant changes in vascular endothelial growth factor (VEGF) expression and release. However, trans-arterial chemoembolization (TACE) used alongside tyrosine-kinase inhibitor (TKI) sorafenib has had its efficacy contested. Most recently, interest in associating Y-90 and TKI has emerged. Furthermore, LDT-led differences in tumor immune microenvironment and immune cell infiltration could be an opportunity to enhance immunotherapy efficacy for HCC patients. Early attempts to coordinate LDT and immunotherapy are being made. We here review LDT techniques exposing current evidence to understand its extant reach and future applications alongside systemic therapy development for HCC.

scholarly journals Indian Society of Vascular and Interventional Radiology Expert Consensus Statements for Ablation in Hepatocellular Carcinoma: Part I

2020 ◽  
Vol 4 (02) ◽  
pp. 098-106 ◽  
Author(s):  
Pankaj Gupta ◽  
Naveen Kalra ◽  
Shyamkumar N. Keshava ◽  
Sreedhara B. Chaluvashetty ◽  
Amar Mukund ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Interventional Radiology ◽  
Indian Society ◽  
Percutaneous Ablation ◽  
Consensus Document ◽  
Consensus Statements ◽  
Small Hccs ◽  
Early Hcc ◽  
Widespread Availability ◽  
Ablative Techniques

AbstractLocoregional therapies play an important role in the management of hepatocellular carcinoma (HCC). Percutaneous ablation is one of the most commonly employed nonsurgical methods for treating very early and early HCC. For small HCCs, ablation is potentially curative and competes with surgical resection. The widespread availability and the spectrum of ablative techniques mandate uniform approach among interventional radiologists. Thus, it is desirable to have a consensus regarding various aspects of liver ablation. This article represents a consensus document of the experts from the Indian Society of Vascular and Interventional Radiology involved in the care of patients with HCC. The statements are presented in two parts.

Multimodality treatment of hepatocellular carcinoma

1998 ◽  
Vol 13 (11-s4) ◽  
pp. S315-S319 ◽  
Author(s):  
ZHAO-YOU TANG ◽  
XIN-DA ZHOU ◽  
ZENG-CHEN MA ◽  
ZHI-QUAN WU ◽  
JIA FAN ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Multimodality Treatment
Sign in / Sign up

Export Citation Format

Share Document